remaining two segments, Integrated Oxides & Derivatives and Specialty Chemicals are expected to resume their earnings from unplanned shutdowns, except IPA which we believe will recover over the next 12-18
continuous improvement in margin from 2Q 2017 to 1Q 2019. The Integrated PET margin improvement since March 2019 in Asia region is expected to benefit IVL globally especially from the recent weakness in PX
continuous improvement in margin from 2Q 2017 to 1Q 2019. The Integrated PET margin improvement since March 2019 in Asia region is expected to benefit IVL globally especially from the recent weakness in PX
leading to margin increase in all commodity products, supporting the increase in crude oil prices. All of this is translating into stronger than anticipated earnings in first half 2021. Transformation
public investment is anticipated to grow at the lower rate compared to last year due to the delay of extra-budget disbursement. For internal stability, headline inflation is predicted to reach 0.7 percent
THB1.225/share for 2019. IVL concurrently undertook several transformative initiatives that were announced on 4th Feb 2020 at its Capital Market Day, which are expected to generate benefits starting in 2020
sales of light vehicles, U-shape recovery is expected with easing of situation and financial support given to Automobile sector by European government. Capital Expenditure Program IVL expects its balance
$ 1.9B. Interest cost is expected to come down for year 2020, thanks to lower benchmark rates. Our net operating debt to equity went up to 1.35 times primarily due to the acquisition of Spindletop
market rewards, are mainly due to better future growth opportunities and lower expected returns. Recent research on the implications of consistently meeting earnings targets still, however, leaves
segment. Increase in crude prices and restocking to support forthcoming seasonal demand has resulted in this trend being reversed in 1Q19. o 2019 is also expected to outperform 2018 as legacy contracts in